Volume 35, Issue 11 pp. 2442-2447

Transplantation

Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients

Sammy Saab,

Corresponding Author

Sammy Saab

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Correspondence

Sammy Saab, MD, MPH, AGAF, FAASLD, 200 Medical Plaza, Suite 214, Los Angeles, CA 90095, USA

Tel: 310 206 6705

Fax: 310 206 4197

e-mail: [email protected]

Search for more papers by this author

Adam Greenberg,

Adam Greenberg

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Edwin Li,

Edwin Li

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Sherona Ngashea Bau,

Sherona Ngashea Bau

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Francisco Durazo,

Francisco Durazo

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Mohammed El-Kabany,

Mohammed El-Kabany

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Steven Han,

Steven Han

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Ronald W. Busuttil,

Ronald W. Busuttil

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Sammy Saab,

Corresponding Author

Sammy Saab

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Correspondence

Sammy Saab, MD, MPH, AGAF, FAASLD, 200 Medical Plaza, Suite 214, Los Angeles, CA 90095, USA

Tel: 310 206 6705

Fax: 310 206 4197

e-mail: [email protected]

Search for more papers by this author

Adam Greenberg,

Adam Greenberg

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Edwin Li,

Edwin Li

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Sherona Ngashea Bau,

Sherona Ngashea Bau

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Francisco Durazo,

Francisco Durazo

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Mohammed El-Kabany,

Mohammed El-Kabany

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Steven Han,

Steven Han

Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

Ronald W. Busuttil,

Ronald W. Busuttil

Department of Surgery, University of California, Los Angeles, Los Angeles, CA, USA

Search for more papers by this author

First published: 24 April 2015

https://doi.org/10.1111/liv.12856

Citations: 39

See Editorial on Page 2354

Handling Editor: Alessio Aghemo

Share a link

Email
Wechat
Bluesky

Abstract

Background & Aims

Hepatitis C is the most common indication for liver transplantation (LT). Recurrent infection is universal and can lead to progressive liver disease. Widespread use of interferon-based therapy has been limited by intolerability and adverse effects.

Methods

We retrospectively evaluated the safety, tolerability, and efficacy of sofosbuvir and simeprevir in the treatment of recurrent hepatitis C in adult (age >18) LT recipients.

Results

Seventy-six percent of the recipients were male and the mean age [±standard deviation (SD)] was 61 (±6.0) years. The mean time (±SD) from LT to treatment initiation was 71.8 (±77.1) months. Of the 26 patients with viral levels measured 4 weeks after starting antiviral therapy, 58% were undetectable. At the end of therapy, viral load was undetectable in all transplant recipients. The 12 week sustained viral response (SVR) was 93%. All recipients were able to complete therapy and no patients required growth factors of blood product transfusion during treatment. No patient required drug interruption of their immunosuppressant therapy.

Conclusion

The use of sofosbuvir and simeprevir is efficacious, safe, and tolerable and should be considered in LT recipients with recurrent HCV who are candidates for antiviral therapy.

References

1Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2013 annual data report: liver. Am J Transplant 2015; 15(Suppl 2): 1–28.
10.1111/ajt.13197
PubMed Web of Science® Google Scholar
2Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384–93.
10.1097/00000658-200109000-00012
CAS PubMed Web of Science® Google Scholar
3Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373–83.
10.1053/j.gastro.2012.02.011
PubMed Web of Science® Google Scholar
4Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250–6.
10.1002/hep.510290122
CAS PubMed Web of Science® Google Scholar
5Agopian VG, Petrowsky H, Kaldas FM, et al. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg 2013; 258: 409–21.
10.1097/SLA.0b013e3182a15db4
PubMed Web of Science® Google Scholar
6Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752–62.
10.1002/hep.25976
CAS PubMed Web of Science® Google Scholar
7Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010; 16: 748–59.
10.1002/lt.22072
CAS PubMed Web of Science® Google Scholar
8Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274–87.
10.1016/j.jhep.2008.05.002
CAS PubMed Web of Science® Google Scholar
9Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132–9.
10.1053/j.gastro.2012.01.030
CAS PubMed Web of Science® Google Scholar
10Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10: 859–67.
10.1002/lt.20157
CAS PubMed Web of Science® Google Scholar
11Saab S, Oh MK, Ibrahim AB, et al. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007; 13: 1032–8.
10.1002/lt.21184
CAS PubMed Web of Science® Google Scholar
12Lawitz E, Sulkowski MS. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756–65.
10.1016/S0140-6736(14)61036-9
CAS PubMed Web of Science® Google Scholar
13 AASLD/IDSA/IAS–USA. When and in whom to initiate HCV therapy. Recommendations for testing, managing, and treating hepatitis C. Available at http://www.hcvguidelines.org/full-report/when-and-whom-initiate-hcv-therapy. Accessed 7 October 2014.
Google Scholar
14Saab S, Manne V, Bau S, et al. Boceprevir in liver transplant recipients. Liver Int 2015; 35: 192–7.
10.1111/liv.12548
CAS PubMed Web of Science® Google Scholar
15Pungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690–700.
10.1002/lt.23669
CAS PubMed Web of Science® Google Scholar
16Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ 2014; 348: g3308.
10.1136/bmj.g3308
PubMed Web of Science® Google Scholar
17Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375–82.
10.1056/NEJMoa1408921
CAS PubMed Web of Science® Google Scholar
18Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Presented at: AASLD 2014; 2014 Nov 7–11; Boston, MA.
Google Scholar
19Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108–17.
10.1053/j.gastro.2014.10.001
CAS PubMed Web of Science® Google Scholar
20Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2015; 61: 41–5.
10.1002/hep.27366
CAS PubMed Web of Science® Google Scholar
21Akhtar E, Manne V, Saab S. Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int 2015; 35: 30–6.
10.1111/liv.12576
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume35, Issue11

November 2015

Pages 2442-2447

Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients

Abstract

Background & Aims

Methods

Results

Conclusion

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients

Abstract

Background & Aims

Methods

Results

Conclusion

References

Citing Literature

References

Related

Information